Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Slides: 1–6 of 6
Add to tray Remove from tray

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Add to tray Remove from tray

Clinically Significant Outcomes of Interest (1 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | physician global assessment | ACR Ped | parent global assessment | active joint count | erythrocyte sedimentation rate | ESR | radiographic
Add to tray Remove from tray

Summary of Study Characteristics Evaluated in the Effectiveness Review: PICOTS

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | NSAIDs | intra-articular corticosteroids | DMARDs | disease status | health status | inflammation | radiographic progression | PICOTs
Add to tray Remove from tray

Evaluating JIA Assessment Instruments (2 of 3)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: ACR Pediatric | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | flare | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | remission | rheumatic | TNF-alpha blockers | juvenile idiopathic arthritis
Add to tray Remove from tray

Evaluating JIA Assessment Instruments: Conclusions (2 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness
Add to tray Remove from tray

Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review

Presentation: Drug Therapy for Rheumatoid Arthritis in Adults
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | oral | disease activity | ACR | radiographic evidence of progression | functional capacity | HAQ | quality of life | SF-36 | DAS
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364